Healthcare

-U.S. FDA grants GB221 rare pediatric disease designation PHILADELPHIA, Feb. 26, 2026 /PRNewswire/ — Gemma Biotherapeutics (“GEMMABio”), a…

Treatments for cardiovascular conditions have never been better. Knowledge about how to improve heart health has steadily improved.…

Sector Overview The stock market today showcases a complex tapestry of trends and fluctuations. The technology sector is…

Will the healthcare sector finally rebound in 2026, after underperforming broader equities in recent years? It’s hard to…

TOP POLICY PRIORITY As demographic pressures mount, China is increasingly looking outward for expertise and investment to upgrade…

As more health systems end gender-affirming care for patients amid a crackdown from the Trump administration, scientists and…

ASX healthcare stock Saluda Medical Inc (ASX: SLD) has endured a rough 12 months. So far in 2026,…

Antibiotic Aftershocks This is part 3 in a three-part series on potential harms from taking antibiotics for dental…

Hospitals and care homes in the UK face “an impending car crash”, experts have warned, as research shows…

We all know smoking raises your risk of lung cancer and a poor diet can lead to diabetes…

Chuluunbaatar Odgerel, a Mongolian patient, consults with medical staff at Ewha Womans University Seoul Hospital in Seoul’s Gangseo…

4 min readRecent research suggests that breast arterial calcification (BAC) picked up on routine mammograms may help predict…

GEMMABio Announces First Patient Dosed in CHARISMA Trial of GB221, Investigational Next‑Generation Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1)